The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.

Int J HyperthermiaJun 23, 2026 (epub)
Clinical ResearchOncology (Medical)

Paul Krahl, Kagayaki Kuroda, Jorge Contreras et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy of capacitive hyperthermia (cHT) as an adjunct treatment in oncology, focusing on randomized phase III trials involving cancer patients undergoing radiotherapy and/or chemotherapy. The review found that cHT improved local control and overall survival in some cervical cancer trials, while no benefits were noted in non-small cell lung cancer. The treatment was generally well tolerated.

Key findings

  • cHT improved local control and overall survival in three out of five cervical cancer trials.
  • Marked increase in tumor response rates was observed in head and neck cancer trials using cHT.
  • No benefit of cHT was found in non-small cell lung cancer trials.
  • Mild to moderate adverse events were the most common side effects associated with cHT.

Why it matters

Understanding the role of adjunctive therapies like capacitive hyperthermia can help clinicians optimize treatment strategies for patients with various types of cancer, potentially improving outcomes in specific populations.

Source

PubMed · PMID 42334174

Published in Int J Hyperthermia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.